Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

Use of unlicensed black salve for cutaneous malignancy

- Featured Image

To the Editor: The most frequently diagnosed cancers in Australia are non-melanoma skin cancers.1 Recommended treatments include surgical excision, radiotherapy and topical chemotherapy for in-situ lesions.2 There has been an increase in sales of lotions and salves that claim to eradicate skin lesions and promote removal of skin cancers. In 2012, the Therapeutic Goods Administration issued a public warning strongly advising patients against the use of red and black salves.3 We report a recent case illustrating the complications resulting from use of these unlicensed products.

A 55-year-old man presented to the emergency department at Princess Alexandra Hospital, Brisbane, with a tissue defect on his right temple (Box). The patient had applied black salve to a lesion, which he believed to be cancerous, over the previous 4 months.

Before the Therapeutic Goods Administration warning, topical preparations such as black and red salves were being sold online to Australians as an alternative treatment for skin cancer. These products contain sanguinarine, a benzylisoquinolone alkaloid derived from bloodroot (Sanguinaria canadensis).3